136866-39-2

Basic information

• Product Name: 1-(3,5-Dichloropyrazin-2-yl)ethanone
• Synonyms: 1-(3,5-Dichloropyrazin-2-yl)ethanone;1-(3,5-dichloro-2-pyrazinyl)ethanone
• CAS NO: 136866-39-2
• Molecular Formula: C₆H₄Cl₂N₂O
• Molecular Weight: 191.01476
• Mol File: 136866-39-2.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-(3,5-Dichloropyrazin-2-yl)ethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(3,5-Dichloropyrazin-2-yl)ethanone(136866-39-2)
• EPA Substance Registry System: 1-(3,5-Dichloropyrazin-2-yl)ethanone(136866-39-2)

Safety Data

• Hazardous Substances Data: 136866-39-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-(3,5-Dichloropyrazin-2-yl)ethanone is used as a key intermediate in the synthesis of N-[4-(1H-Pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]-sulfonamides. These compounds have been identified as highly active and selective inhibitors of the Serumand Glucocorticoid-Induced Kinase 1 (SGK1). SGK1 is a protein kinase that plays a role in various cellular processes, including cell survival, proliferation, and ion transport. Inhibiting SGK1 has potential therapeutic applications in treating conditions such as cancer, cardiovascular diseases, and inflammatory disorders.
Additionally, 1-(3,5-Dichloropyrazin-2-yl)ethanone can be utilized in the development of other bioactive molecules with diverse pharmacological properties, contributing to the advancement of drug discovery and the treatment of various diseases.

Upstream product

• 313339-92-3 3,5-dichloro-pyrazine-2-carbonitrile 
• 676-58-4 methylmagnesium chloride 
• 75-16-1 methylmagnesium bromide 
• 312736-50-8 3,5-dichloropyrazine-2-carboxamide 
• 136866-33-6 1-(3,5-dichloro-pyrazin-2-yl)-ethanol 
• 136866-27-8 3,5-dichloro-pyrazine-2-carbaldehyde 

Downstream Products

• 1426214-82-5 [4-(3-methyl-1H-pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]-carbamic acid tert-butyl ester 
• 1426214-81-4 [4-(5-acetyl-6-chloro-pyrazin-2-yl)-phenyl]-carbamic acid tert-butyl ester 
• 1314936-02-1 3,5-dichloro-2-ethylpyrazine 
• 1426214-83-6 2-cyano-5-methyl-N-[4-(3-methyl-1H-pyrazolo[3,4-b]pyrazin-6-yl)phenyl]benzenesulfonamide 
• 1426214-73-4 2,3-dichloro-N-[4-(3-methyl-1H-pyrazolo[3,4-b]pyrazin-6-yl)phenyl]benzenesulfonamide 
• 1426214-74-5 N-[4-(5-acetyl-6-chloro-pyrazin-2-yl)-phenyl]-2,3-dichloro-benzenesulfonamide 

Relevant articles and documents

Synthesis method of 3,5-dichloro-6-ethylpyrazineformamide

The invention discloses a synthetic method of 3,5-dichloro-6-ethylpyrazine formamide, and relates to the technical field of intermediate for synthesizing gilteritinib. The method is technically characterized by comprising the following steps: heating 2,6-dichloropyrazine and formamide to 70-130 DEG C, and carrying out free radical oxidation reaction under the action of persulfate to obtain 3,5-dichloropyrazine formamide; carrying out heating reflux on 3,5-dichloropyrazine formamide for 3-6 h under the action of a dehydrating agent, and synthesizing 3,5-dichloropyrazine formonitrile through dehydration; carrying out a Grignard reactionon the 3,5-dichloropyrazine formonitrile in an organic solvent A under the action of a methylation reagent to prepare 3,5-dichloro-2-acetylpyrazine; under theaction of an acidic catalyst and a silicon-hydrogen reducing agent, reducing the 3,5-dichloro-2-acetyl pyrazine in an organic solvent B to obtain 3,5-dichloro-2-ethyl pyrazine; and heating the 3,5-dichloro-2-ethyl pyrazine and formamide to 50-120 DEG C, and carrying out free radical oxidation reaction under the action of persulfate to obtain the 3,5-dichloro-6-ethylpyrazine formamide. According to the invention, the operation method is simple, the reaction conditions of the synthesis process are mild, the cost is reduced, and meanwhile high economic benefits can be brought.

CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF

Disclosed herein, inter alia, are compounds and methods of use thereof for the modulation of CCR4 activity.

CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF

Disclosed herein, inter alia, are compounds and methods of use thereof for the modulation of chemokine receptor activity.

N-[ 4 - (1H-pyrazolo [3,4-b] pyrazin-6-yl)-phenyl]-sulfamide and their use as medicaments

The invention relates to N-[4-(1H-pyrazolo[3,4-b] pyrazine-6-yl)-phenyl]-sulfonamides of a formula I. In the formula I, Ar, R1, R2 and n have meanings as shown in the claims. The compounds of the formula I are compounds which are valuable, have pharmacological activity and can adjust the activity of protein kinase, particularly the activity of serum and glucocorticoid induced kinase (SGK), and more particularly the activity of serum and glucocorticoid induced kinase isoform (SGK-1, SGK1). The compounds are suitable for treating diseases with inappropriate activity of the SGK, such as degenerative joint diseases or inflammatory process such as osteoarthritis or rheumatism. The invention also relates to a method for preparing the compounds of the formula I, an application of the compounds serving as the medicines and medicine compositions containing the compounds.

Discovery of N-[4-(1H-pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]-sulfonamides as highly active and selective SGK1 inhibitors

From a virtual screening starting point, inhibitors of the serum and glucocorticoid regulated kinase 1 were developed through a combination of classical medicinal chemistry and library approaches. This resulted in highly active small molecules with nanomolar activity and a good overall in vitro and ADME profile. Furthermore, the compounds exhibited unusually high kinase and off-target selectivity due to their rigid structure. (Chemical Presented).

N-[ 4-(1H-pypazolo [3, 4-b] aminopyrazine-6-yl)-phenyl]-and its use as a chemical acylsulfonamide

PROBLEM TO BE SOLVED: To provide a compound effective for the treatment of diseases due to the inadequacy of serum and glucocorticoid adjustment kinase (SGK) activities, for instance, degenerative arthropathy or inflammatory process, e.g., osteoarthritis or rheumatism, to provide its use as a drug, and to provide a pharmaceutical composition containing the same. SOLUTION: The compound is represented by formula I ( wherein, Ar is selected from the group consisting of phenyl and five- or six-membered monocyclic aromatic heterocyclic rings each containing a ring heteroatom selected from the group consisting of nitrogen, oxygen and sulfur; R1 is H, amino or the like; R2 is a halogen atom, alkyl or the like; and n is 0, 1 or 2). COPYRIGHT: (C)2013,JPOandINPIT

N-[4-(1h-pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]-sulfonamides and their use as pharmaceuticals

The present invention relates to N-[4-(1H-pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]-sulfonamides of the formula I, wherein Ar, R1, R2 and n have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds which modulate protein kinase activity, specifically the activity of serum and glucocorticoid regulated kinase (SGK), in particular of serum and glucocorticoid regulated kinase isoform 1 (SGK-1, SGK1), and are suitable for the treatment of diseases in which SGK activity is inappropriate, for example degenerative joint disorders or inflammatory processes such as osteoarthritis or rheumatism. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use as pharmaceuticals, and pharmaceutical compositions comprising them.

N-[4-(1H-PYRAZOLO[3,4-B]PYRAZIN-6-YL)-PHENYL]-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS

The present invention relates to N-[4-(1H-pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]-sulfonamides of the formula (I), (R2)n wherein Ar, R1, R2 and n have the meanings indicated in the claims. The compounds of the formula (I) are valuable pharmacologically active compounds which modulate protein kinase activity, specifically the activity of serum and glucocorticoid regulated kinase (SGK), in particular of serum and glucocorticoid regulated kinase isoform 1 (SGK-1, SGK1), and are suitable for the treatment of diseases in which SGK activity is inappropriate, for example degenerative joint disorders or inflammatory processes such as osteoarthritis or rheumatism. The invention furthermore relates to processes for the preparation of the compounds of the formula (I), their use as pharmaceuticals, and pharmaceutical compositions comprising them.

N-[4-(1H-PYRAZOLO[3,4-B]PYRAZIN-6-YL)-PHENYL]-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS

The present invention relates to N-[4-(1H-pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]- sulfonamides of the formula I, wherein Ar, R1, R2 and n have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds which modulate protein kinase activity, specifically the activity of serum and glucocorticoid regulated kinase (SGK), in particular of serum and glucocorticoid regulated kinase isoform 1 (SGK-1, SGK1), and are suitable for the treatment of diseases in which SGK activity is inappropriate, for example degenerative joint disorders or inflammatory processes such as osteoarthritis or rheumatism. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use as pharmaceuticals, and pharmaceutical compositions comprising them.

N-[4-(1H-PYRAZOLO[3,4-B]PYRAZIN-6-YL)-PHENYL]-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS

The present invention relates to N-[4-(1H-pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]-sulfonamides of the formula I, wherein Ar, R1, R2 and n have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds which modulate protein kinase activity, specifically the activity of serum and glucocorticoid regulated kinase (SGK), in particular of serum and glucocorticoid regulated kinase isoform 1 (SGK-1, SGK1), and are suitable for the treatment of diseases in which SGK activity is inappropriate, for example degenerative joint disorders or inflammatory processes such as osteoarthritis or rheumatism. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use as pharmaceuticals, and pharmaceutical compositions comprising them